Big News: Mounjaro® (Tirzepatide) Lowers Risk of Heart Attack, Stroke, and Cardiovascular Death
Today, Eli Lilly announced groundbreaking results from the SURPASS-CVOT trial showing that Mounjaro® (tirzepatide), a once-weekly injectable medication used for type 2 diabetes (and marketed as Zepbound® for obesity), reduced the risk of major adverse cardiovascular events (MACE) by 28% in people with type 2 diabetes and established heart disease.
MACE includes cardiovascular death, nonfatal heart attack, or nonfatal stroke — three of the most serious risks faced by people living with type 2 diabetes and cardiovascular disease. The benefit was consistent across all three studied doses of Mounjaro® (5 mg, 10 mg, and 15 mg).
You can read Lilly’s official press release here.
How Does This Compare to Other Medications?
- Mounjaro® (tirzepatide):
- 28% reduction in heart attack, stroke, or cardiovascular death in people with type 2 diabetes and established heart disease.
- Ozempic® (semaglutide):
- 26% reduction in MACE in people with type 2 diabetes and cardiovascular disease (SUSTAIN-6 trial).
- Wegovy® (semaglutide for obesity):
- 20% reduction in MACE in people with cardiovascular disease but without diabetes (SELECT trial).
- Zepbound® (tirzepatide for obesity):
- A large cardiovascular outcomes trial (SURMOUNT-MMO) is currently underway in people without diabetes, with results expected around 2027.
Why This Matters
Cardiovascular disease remains the leading cause of death in people with type 2 diabetes. For patients living with both diabetes and heart disease, these new findings confirm that Mounjaro® not only helps with blood sugar and weight loss, but also reduces the risk of life-threatening cardiovascular events.
Key Takeaways for Patients
- Mounjaro® cut cardiovascular risk by 28% in people with type 2 diabetes and heart disease.
- This compares favorably to semaglutide (Ozempic®/Wegovy®).
- Wegovy® has already shown benefit in people without diabetes — and we expect Zepbound® data in 2027.
- These medications are changing the future of diabetes, obesity, and cardiovascular care.
At Clinical Nutrition Center, we are encouraged by these findings and will continue to keep you updated as more information becomes available. Medications like Mounjaro® and Wegovy® are proving to be more than just tools for managing weight and blood sugar — they are also powerful allies in protecting your heart.
